Rationale: Activity of the large conductance Ca 2؉ -activated K ؉ (BK) channels is profoundly modulated by its ␤ 1 subunit (BK-␤ 1 ). However, BK-␤ 1 expression is downregulated in diabetic vessels. The ubiquitin-proteasome system (UPS) is a major mechanism of intracellular protein degradation. Whether UPS participates in BK-␤ 1 downregulation in diabetic vessels is unknown. 1 V146A (a mutant without the PDZ-binding motif) . After cotransfection with atrogin-1, the ubiquitination of Flag-hSlo-␤ 1 was increased by 1.91-fold, compared with that of hSlo-␤ 1 V146A, whereas cotransfection with atrogin-1⌬F (a nonfunctional mutant without the F-box motif) had no effect. Moreover, inhibition of Akt signaling attenuated the phosphorylation of forkhead box O transcription factor (FOXO)-3a and enhanced atrogin-1 expression, which in turn suppressed BK-␤ 1 protein levels in human CASMCs.
T he large conductance Ca 2ϩ -activated K ϩ (BK) channels play an important role in the regulation of vascular physiology. Functional BK channels in coronary arterial smooth muscle cells (CASMCs) are composed of the poreforming ␣ subunits (BK-␣, encoded by the Slo gene) and the regulatory ␤ 1 subunits (BK-␤ 1 ) in 4:4 stoichiometry. However, BK channel function is impaired in diabetes, 1, 2 which is associated with microvessel complications. Recently, we and other investigators have reported that impaired BK channel activation was attributable to reduced BK-␤ 1 expression in diabetic vessels. 3, 4 However, the underlying molecular mechanisms is unknown.
The ubiquitin-proteasome system (UPS) accounts for 80% to 90% of intracellular protein turnover. 5 UPS-mediated protein degradation involves 3 enzyme systems: ubiquitinactivation enzyme E1, ubiquitin-conjugating enzyme E2, and ubiquitin ligase E3. 6 There are 1 E1, Ͼ25 E2, and Ͼ1000 E3 enzymes. Each E3 recognizes a specific motif on substrate proteins.
F-box only proteins (FBXOs) are key components of the Skp1-Cullin-F-box (SCF) type ubiquitin ligase complex, functioning as sites for enzyme-substrate interaction. 7 subtypes and are abundantly expressed in myocardium and skeletal muscles. 9, 10 Atrogin-1 may bind to the PDZbinding motif (T/S-X-V; X is any amino acid) in substrates. 9 Interestingly, the PDZ-binding motif is present in most BK-␤ 1 isoforms in different species including human. However, the role of FBXOs in the regulation of BK-␤ 1 expression is unknown. Here, we hypothesized that enhanced UPS activity facilitates BK-␤ 1 protein degradation in diabetes. We found that expression of atrogin-1 and FBXO-9 was augmented in human CASMCs under highglucose (HG) culture and in streptozotocin (STZ)-induced diabetic rat vessels, leading to downregulation of BK-␤ 1 expression. Moreover, expression of FBXOs and BK-␤ 1 was regulated by FOXO-3a phosphorylation. Hence, we have delineated a novel fundamental mechanism that underlies vascular BK-␤ 1 dysfunction in diabetes.
Methods
Male Sprague-Dawley rats were used. Handling and care of animals were approved by the Institutional Animal Care and Use Committee of Mayo Clinic.
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org. Figure 1A shows whole-cell K ϩ currents from freshly isolated CASMCs of control and STZ-induced diabetic rats before and after application of 100 nmol/L iberiotoxin (IBTX) (a specific BK channel inhibitor). The currentvoltage curves of IBTX-sensitive K ϩ currents (defined as BK currents) were significantly decreased by 4.5-fold in diabetic rats, compared with control. DHS-1 (100 nmol/L, a specific BK-␤ 1 activator) applied to the cytoplasmic membrane surface of CASMCs remarkably increased BK channel open probability from 0.11Ϯ0.04 at baseline to 0.33Ϯ0.11 with DHS-1 (PϽ0.05 versus baseline) in control rats but had no effect in diabetic rats ( Figure 1B ), suggesting that the ␤ 1 -mediated BK channel activation is lost.
Results

Reduced BK Current Density and Impaired DHS-1-Mediated Channel Activation in CASMCs of Diabetic Rats
Downregulated BK-␤ 1 Expression and Enhanced BK-␤ 1 Ubiquitination in Diabetic Vessels and in Human CASMCs With HG Culture
BK-␤ 1 protein levels were decreased by 3.06Ϯ0.07-fold (PϽ0.05 versus control) in STZ-induced diabetic rats ( Figure 1C ) and by 2.10Ϯ0.09-fold in human CASMCs with HG (22 mmol/L), compared with those with normal glucose (NG) (5 mmol/L, PϽ0.05) ( Figure 1D ), whereas BK-␣ expression remained unchanged. The effects of HG on BK-␤ 1 downregulation were detectable at day 7 and plateaued at days 10 to 14 of HG culture (Online Figure I) . However, BK-␤ 1 mRNA level was not reduced in diabetic rats but actually increased in human CASMCs cultured with HG (Online Figure II) .
Accordingly, the ubiquitination of BK-␤ 1 in diabetic rat aortas and in human CASMCs cultured with HG was increased by 3.23Ϯ0.36-fold (PϽ0.05 versus controls) and by 2.40Ϯ0.33fold (PϽ0.05 versus NG), respectively ( Figure 1E ).
Increased FBXO Expression in Diabetic Rat Vessels and in Human CASMCs With HG Culture
Atrogin-1 and FBXO-9 were expressed in rat aortas and in human CASMCs (Online Figure III) . Protein levels of FBXO-9 and atrogin-1 were increased in aortas of STZinduced diabetic rats by 1.65Ϯ0.16-fold and 4.87Ϯ1.17fold, respectively (PϽ0.05 versus control in both) ( Figure  2A ), as well as in human CASMCs cultured with HG by 2.43Ϯ0.27-fold and 2.33Ϯ0.36-fold, respectively (PϽ0.05 versus NG in both) ( Figure 2B ). Seventy-two hours after FBXO-9 small interfering (si)RNA (50 nmol/L) was transfected into human CASMCs, FBXO-9 protein level was suppressed by 80%, whereas BK-␤ 1 expression was increased by 1.65Ϯ0.16-fold, compared with control siRNA (PϽ0.05) ( Figure 2C ).
After 24 hours of incubation with 0.1 mol/L doxorubicin (DXR) (a FBXO activator), 11 BK-␤ 1 expression was reduced by 1.92Ϯ0.11-fold (PϽ0.05 versus control) in NG ( Figure 2D ) and by 1.79Ϯ0.05-fold (PϽ0.05 versus control) in HG ( Figure 2E ). The DXR effects were abolished by 4-hour treatment with 10 mol/L MG-132 (a proteasome inhibitor). BK channel openings were less frequent, with no response to DHS-1 in nondiabetic rat CASMCs after treatment with DXR (PϭNS versus baseline). In CASMCs incubated with DXRϩMG-132, however, BK channel activity was robust in the presence of DHS-1 (PϽ0.05 versus baseline) ( Figure 2F ), consistent with the immunoblotting results.
Non-standard Abbreviations and Acronyms
Lack of the PDZ-Binding Motif in hSlo-␤ 1 Abolished UPS-Mediated Protein Degradation
The PDZ-binding motif is well conserved in BK-␤ 1 (Figure 3A) . We measured protein expression of Flag-hSlo-␤ 1 wt and Flag-hSlo-␤ 1 V146A (a mutation in the PDZbinding motif) after cotransfection with ubiquitin and atrogin-1 or atrogin-1⌬F (a nonfunctional mutant with deletion of the F-box). Seventy-two hours after transfection, expression of hSlo-␤ 1 wt was 2.16Ϯ0.16-fold lower than that of hSlo-␤ 1 V146A (PϽ0.05) ( Figure 3B ). Also, ubiquitination of hSlo-␤ 1 wt was 1.91Ϯ0.08-fold higher than that of hSlo-␤ 1 V146A (PϽ0.05) in cells cotransfected with atrogin-1, whereas atrogin-1⌬F transfection had no effect ( Figure 3C ). Hence, our results suggest that FBXO interacts with BK-␤ 1 through the PDZ-binding motif and facilitates BK-␤ 1 ubiquitination and degradation.
Regulation of Atrogin-1 and BK-␤ 1 Expression by Akt/FOXO-3a Signaling in Human CASMCs
We atrogin-1 expression and 3.22Ϯ0.06-fold reduction (PϽ0.05 versus control) in BK-␤ 1 expression in human CASMCs (Figure 4C ).
Discussion
The BK-␤ 1 subunit significantly enhances BK channel voltage sensitivity and Ca 2ϩ cooperativity, 4 and its physiological importance is underscored by BK-␤ 1 knockout mice, which showed increases in myogenic tone and arterial blood pressure, with uncoupling of Ca 2ϩ sparks to BK channels in vascular smooth muscle cells (SMCs). 12 We and others have demonstrated that BK channel dysfunction in both type I and type II diabetic vessels is associated with reduced BK-␤ 1 expression. 3, 4 In this study, we provided the first evidence that downregulation of BK-␤ 1 expression in vasculature was attributable to increased FBXO expression in diabetes and in HG culture conditions. Abnormal expression of atrogin-1 is associated with muscle diseases, and its increased expression leads to skeletal muscle atrophy, 9 whereas its reduced expression produces cardiac hypertrophy. 10 We have found that atrogin-1 and FBXO-9 expression are upregulated in vascular SMCs in diabetes and HG. This upregulation of FBXOs plays a pivotal role in UPS-mediated BK-␤ 1 degradation and BK channel malfunction. Perturbation in atrogin-1 and hSlo-␤ 1 interaction attenuated hSlo-␤ 1 ubiquitination and preserved its protein level.
Atrogin-1 and FBXO-9 are the target genes of FOXO-3a. We found that in diabetes and in human CASMCs with HG, FOXO-3a phosphorylation level was significantly reduced, accompanied by enhanced FBXO expression. The changes in FOXO-3a, FBXOs, and BK-␤ 1 expression in human CASMCs with HG were mimicked by PI3K/Akt inhibition. It is well known that the PI3K/Akt pathway is activated by insulin and suppressed by protein kinase C. Insulin receptor signaling is diminished and protein kinase C activity is upregulated in type I and type II diabetes, and these may lead to enhanced FBXO transcription and impaired BK channel function ( Figure 4D ). Hence, our findings provide novel insights into the pathophysiology of HG (B) . C, FBXO-9 siRNA suppressed FBXO-9 but enhanced BK-␤ 1 expression in human CASMCs. D and E, BK-␤ 1 expression in human CASMCs cultured with NG (D) and HG (E) after treatment with 0.1 mol/L DXR (24 hours), 10 mol/L MG-132 (4 hours), or DXR (24 hours) plus MG-132 (4 hours). F, DHS-1 had no effect in rat CASMCs pretreated with DXR, but BK channel activation was preserved in cells treated with DXRϩMG-132.
Figure 3. Mutation in the PDZ-binding motif of hSlo-␤ 1 prevented hSlo-␤ 1 ubiquitination and degradation. A,
Sequence alignment of human, rabbit, cattle, rat, and mouse KCNMB1 cDNA shows a conserved PDZ-binding motif. , applied mutation site. B, Seventy-two hours after cotransfection with atrogin-1 and ubiquitin, Flag-hSlo-␤ 1 V146A expression was significantly higher than that of Flag-hSlo-␤ 1 wt. C, Immunoprecipitates of anti-Flag antibody against HEK293 cell lysates with following transfection conditions were resolved and blotted against anti-ubiquitin antibody: no transfection, Flag-hSlo-␤ 1 /ubiquitin, Flag-hSlo-␤ 1 /atrogin-1/ubiquitin, Flag-hSlo-␤ 1 V146A/atrogin-1/ubiquitin, and Flag-hSlo-␤ 1 /atrogin-1⌬F/ubiquitin. diabetic vasculopathy in both type 1 and type 2 diabetes mellitus and render BK-␤ 1 as a potential therapeutic target in treatment of these conditions.
